CliffBio
biologic

Lamzede

velmanase alfa-tycv

Loss of exclusivityFebruary 2035projected — 12-year biologic exclusivity estimate
CompanyChiesi Farmaceutici S.p.A. →See this company's full patent-cliff portfolio

Drug detail

Brand nameLamzede
Active ingredientvelmanase alfa-tycv
Strength10MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalFebruary 2023
Marketing statusRx

More from Chiesi Farmaceutici S.p.A.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.